SecBot SecBot
8-K ·Filed Nov 9, 2026

CRL

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
NEUTRAL
Impact 5/10
Horizonmonths Processed7d 20h ago SEC0000950103-26-017127
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor the closing timeline and regulatory approvals in Hong Kong and the Cayman Islands. The acquisition is expected to be neutral to non-GAAP EPS in 2027, so any guidance revision or update on accretion timing would be a key catalyst.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$353.34
T+0 close · Nov 9, 2026 · via day close
Latest settled
−5.04%
T+5 · $335.52
Vs SPY
−3.35%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $353.34entry
  2. T+1 · 7d ago −2.13%α −1.77% · $345.80
  3. T+5 · 19h ago −5.04%α −3.35% · $335.52
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Charles River Laboratories announced it has entered definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, plus up to $75 million in contingent earnout payments. The transaction is expected to close in the first half of 2027 and is expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter.

Key Facts

  • Purchase price of approximately $470 million in cash for Frontage's bioanalysis and DMPK operations
  • Additional contingent payments of up to $75 million based on future performance
  • Transaction expected to close during first half of 2027
  • Acquired businesses represented approximately 40% of Frontage's total 2025 revenue of $256.7 million
  • Acquisition expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter
  • Financed through Charles River's credit facility and available cash
  • Acquired businesses to be reported as part of the DSA segment
  • Acquisition involves a consortium with Tigermed and Dr. Song Li to first take Frontage private

Financial Impact

Approximately $470 million cash purchase price plus up to $75 million contingent earnout; acquired businesses had ~$102.7 million in 2025 revenue (40% of Frontage's $256.7M total). Transaction represents about 3.1% of CRL's $15.0B market cap.

revenuenon-GAAP EPSdebt

Risk Factors

  • Transaction subject to shareholder, regulatory, and court approvals in multiple jurisdictions
  • Integration risk and potential loss of clients or key personnel from acquired business
  • Uncertainty around contingent earnout payments and total consideration
  • Financing through credit facility increases leverage

Market Snapshot

Exchange
NYSE
Sector
Services-Commercial Physical & Biological Research
Analyst Consensus
77% bullish (22 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000950103-26-017127
Document: dp256497_8k.htm0000950103-26-017127
Document: 0000950103-26-017127-index-headers.html0000950103-26-017127
Document: 0000950103-26-017127-index.html0000950103-26-017127
Document: 0000950103-26-017127.txt0000950103-26-017127

Track record

17 reports on CRL

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +44.25% at T+60 after the Aug 5, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $333.18 Now $335.52 +0.70% settles Dec 15
  2. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $345.80 Now $335.52 −2.97% settles Dec 9
  3. Nov 9, 20267d ago 8-K Neutral 5/10 Viewing Entry $353.34 Now $335.52 −5.04% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $313.02 Now $335.52 +7.19% settles Dec 4
  5. Nov 4, 202612d ago 8-K Bullish 6/10 Entry $326.29 Now $335.52 +2.83% settles Dec 3
  6. Oct 26, 202621d ago Insider Cluster Neutral 2/10 Entry $358.84 Now $335.52 −6.50% settles Nov 24
  7. Oct 22, 202625d ago 144 Neutral 2/10 Entry $345.37 Now $335.52 −2.85% settles Nov 20
  8. Oct 21, 202626d ago Institutional Cluster Bullish 4/10 Entry $339.66 Now $335.52 −1.22% settles Nov 19
  9. Sep 24, 20267w ago 8-K Bullish 6/10 Entry $294.44 to $339.66 Now $335.52 +13.95% ▲ +15.36% +15.78% vs SPY
  10. Aug 27, 202611w ago Insider Cluster Neutral 3/10 Entry $291.50 to $294.59 Now $335.52 +15.10% ▲ +1.06% +1.55% vs SPY
Showing 10 of 17

US Market Status

Market Closed · Opens in 7h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026